Answers are grounded in this paper and cite their sources.
Purpose: To assess the 12-month outcomes in subjects developing macular neovascularization (MNV) during intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Methods: This research was conducted as a case-controlled, retrospective study of AMD subjects undergoing IVA treatment for GA from two private practice institutions. Subjects were divided into 1) a Study Group of patients who developed MNV and then underwent anti-vascular endothelial growth factor (VEGF) therapy during the study period, and 2) a Control Group of patients who were complication-free during the study period. Both cohorts had a baseline Snellen visual acuity of ≥ 20/200, a baseline GA total area of ≥ 1 mm 2 and ≤ 17.5 mm 2 , and 12 months of follow-up after initiation of IVA for GA. Results: There were 56 patients analyzed. There were no significant differences in baseline features between cohorts. The Study Group had a greater decrease in visual acuity [− 0.22 logMAR (− 0.27 to − 0.17) versus − 0.06 logMAR (− 0.12 to 0.00); p=< 0.0001], and greater GA total lesion growth [1.78 mm 2 (1.53– 2.03) versus 0.78 mm 2 (0.54– 1.02); p=< 0.0001] during the 12-month study period compared to the Control Group. Conclusion: Patients developing MNV while undergoing IVA treatment for GA secondary to AMD have worse clinical outcomes despite undergoing anti-VEGF therapy compared to patients who were complication-free at 12-months. This highlights the seriousness of MNV in this patient population and may help specialists counsel patients when considering treatment for GA secondary to AMD.
No takes yet. Share an insight, caveat, or question.
Rush et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: